These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2785079)

  • 1. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients.
    Lewis JH; Ranard RC; Caruso A; Jackson LK; Mullick F; Ishak KG; Seeff LB; Zimmerman HJ
    Hepatology; 1989 May; 9(5):679-85. PubMed ID: 2785079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatal hepatotoxicity following oral administration of amiodarone.
    Richer M; Robert S
    Ann Pharmacother; 1995 Jun; 29(6):582-6. PubMed ID: 7663029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amiodarone hepatotoxicity. A clinicopathologic study of five patients.
    Rigas B; Rosenfeld LE; Barwick KW; Enriquez R; Helzberg J; Batsford WP; Josephson ME; Riely CA
    Ann Intern Med; 1986 Mar; 104(3):348-51. PubMed ID: 3946978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure.
    Mattar W; Juliar B; Gradus-Pizlo I; Kwo PY
    J Gastrointestin Liver Dis; 2009 Dec; 18(4):419-23. PubMed ID: 20076813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity.
    Pollak PT; Sharma AD; Carruthers SG
    Am J Cardiol; 1990 May; 65(18):1185-91. PubMed ID: 2337027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Amiodarone-induced liver dysfunctions].
    Gassanov N; Caglayan E; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Jul; 135(27):1372-4. PubMed ID: 20589584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction.
    Kum LC; Chan WW; Hui HH; Wong GW; Ho SS; Sanderson JE; Yu CM; Fung JW
    Clin Cardiol; 2006 Jul; 29(7):295-9. PubMed ID: 16881537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How toxic is amiodarone to the liver?
    Pollak PT
    J Gastrointestin Liver Dis; 2010 Mar; 19(1):11-3. PubMed ID: 20361068
    [No Abstract]   [Full Text] [Related]  

  • 9. Amiodarone-induced acute hepatotoxicity.
    Rao U; Agarwal A
    Eur J Clin Pharmacol; 2012 Apr; 68(4):449-50. PubMed ID: 21989920
    [No Abstract]   [Full Text] [Related]  

  • 10. Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports.
    Tsuda T; Tada H; Tanaka Y; Nishida N; Yoshida T; Sawada T; Sakata K; Hayashi K; Kawashiri MA; Oyama T; Sasaki M; Kurose N; Yamagishi M
    J Med Case Rep; 2018 Apr; 12(1):95. PubMed ID: 29653592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.
    Lewis JH; Zimmerman HJ; Benson GD; Ishak KG
    Gastroenterology; 1984 Mar; 86(3):503-13. PubMed ID: 6319220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity.
    Giannattasio F; Salvio A; Varriale M; Picciotto FP; Di Costanzo GG; Visconti M
    Ann Ital Med Int; 2002; 17(3):180-4. PubMed ID: 12402666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathologic analysis of suspected amiodarone hepatotoxicity.
    Lewis JH; Mullick F; Ishak KG; Ranard RC; Ragsdale B; Perse RM; Rusnock EJ; Wolke A; Benjamin SB; Seeff LB
    Hum Pathol; 1990 Jan; 21(1):59-67. PubMed ID: 2403975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity associated with amiodarone therapy.
    Flaharty KK; Chase SL; Yaghsezian HM; Rubin R
    Pharmacotherapy; 1989; 9(1):39-44. PubMed ID: 2646621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone.
    Merz T; Fuller SH
    Am J Health Syst Pharm; 2007 Sep; 64(17):1818-21. PubMed ID: 17724362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic Dysfunction in Patients Receiving Intravenous Amiodarone.
    Hashmi A; Keswani NR; Kim S; Graham DY
    South Med J; 2016 Feb; 109(2):83-6. PubMed ID: 26840961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease.
    Guigui B; Perrot S; Berry JP; Fleury-Feith J; Martin N; Métreau JM; Dhumeaux D; Zafrani ES
    Hepatology; 1988; 8(5):1063-8. PubMed ID: 3417226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute hepatitis following amiodarone administration].
    Tagliamonte E; Cice G; Ducceschi V; Mayer MS; Iacono A
    Minerva Cardioangiol; 1997 Sep; 45(9):451-6. PubMed ID: 9446068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early-onset acute toxic hepatitis induced by intravenous amiodarone administration].
    González Galilea A; García Sánchez MV; la Mata García M; Miño Fugarolas G
    Gastroenterol Hepatol; 2002; 25(6):392-4. PubMed ID: 12069701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
    Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
    Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.